ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ Ở BỆNH NHÂN VIÊM GAN VI RÚT C MẠN

Abstract

Background: Chronic hepatitis C can progress to liver fibrosis, cirrhosis, and liver cancer. Early treatment offers significant benefits for patients. Objective: To describe the clinical and paraclinical characteristics and evaluate treatment outcomes in patients with chronic hepatitis C at Can Tho Central General Hospital in 2024–2025. Subjects and methods: A cross-sectional descriptive study was conducted on 42 patients with chronic hepatitis C treated with the Sofosbuvir/Velpatasvir regimen for 12 weeks. Results: Through research on the treatment of 42 patients with chronic hepatitis C virus. The average age was 55.64 ± 14.67 years. 90.5% had been diagnosed for over one year. 47.6% of patients presented with at least one clinical symptom, most commonly fatigue (45.2%) and loss of appetite (33.3%). Mean ALT was 110.19 ± 115.90 U/L, and mean AST was 84.95 ± 75.36 U/L. High viral load (≥ 4 x 10⁵ IU/ml) was observed in 76.2% of patients. Sustained virological response (SVR) at 12 weeks was achieved in 100% of cases. ALT and AST levels decreased post-treatment. Adverse effects were reported in 21.4% of patients, but none were serious or required treatment discontinuation. Conclusion: The 12-week Sofosbuvir/Velpatasvir regimen is highly effective and well-tolerated in the treatment of chronic hepatitis C, with a 100% SVR and no serious adverse events.